TABLE 3.

Methylation frequency of candidate gene and two-gene marker panels in different stages of epithelial ovarian carcinoma.

	Gene	Stage I/II (%)		Stage III (%)		Stage IV (%)
		Positive/Total	Positive (%)	Positive/Total	Positive (%)	Positive/Total	Positive (%)
TISSUE	HOXA9	16/20	80	44/54	81.5	10/11	90.9
	HIC1	14/20	70	46/54	85.2	8/11	72.7
	SOX1	14/20	70	45/54	83.3	8/11	72.7
	RASSF1A	14/20	70	38/54	70.4	9/11	81.8
	SFRP1	14/20	70	41/54	75.9	8/11	72.7
	SPARC	11/20	55	35/54	64.8	6/11	54.5
	DAPK1	14/20	70	39/54	72.2	6/11	54.5
	HOXA9+HIC1	16/20	80	49/54	90.7	10/11	90.9
	HIC1+SOX1	14/20	70	47/54	87.0	9/11	81.8
	SOX1+HOXA9	15/20	75	46/54	85.2	9/11	81.8
	HOXA9+RASSF1A	13/20	65	42/54	77.8	9/11	81.8
	HIC1+SFRP1	14/20	70	45/54	83.3	8/11	72.7
	DAPK1+SOX1	14/20	70	41/54	75.9	6/11	54.5
SERUM	HOXA9	7/10	70	17/30	56.7	4/5	80
	HIC1	7/10	70	21/30	70	4/5	80
	SOX1	7/10	70	13/30	43.3	4/5	80
	HOXA9+HIC1	10/10	100	24/30	80	4/5	80
	HIC1+SOX1	10/10	100	21/30	70	5/5	100
	SOX1+HOXA9	8/10	80	17/30	56.7	4/5	80